Three-year event-free survival (EFS) and OS for patients in the four major subtypes were 75.8 and 89.8% for ALK-positive ALCL; 50.0 and 67.5% for AITL; 45.7 and 62.1% for ALK-negative ALCL; 41.1 and 53.9% for PTCL-NOS. Here, ALK is linked to angioimmunoblastic T-cell lymphoma.